Physician Satisfaction With Lecanemab in Early Alzheimer's Disease: Real‐World Insights From Prescribers in the United States
Perception of lecanemab's effectiveness and safety by neurologists was favorable, based on interim data. From the neurologist's perspective, both patients and their care partners were also satisfied with lecanemab. In the full data set analysis (data cutoff: May 23, 2025), perspectives on effectiveness and safety of lecanemab and satisfaction rates will be further explored.
Authors
- Curtis P. Schreiber
- Paul Ernest Schulz (ORCID: https://orcid.org/0000-0003-0676-002X)
- Daryl Jones
- David C. Weisman
- Michael Rosenbloom (ORCID: https://orcid.org/0000-0002-2768-9501)
- Christian Camargo
- Gregory Cooper
- Brooke Allen
- Samuel Giles
- Cara Leahy
- Jose Soria‐Lopez
- Courtney Adams
- Marwan N. Sabbagh
- Martin Sadowski
Institutions
- Allen Institute for Brain Science (US)
- Stone Clinic (US)
- Barrow Neurological Institute (US)
- University of Miami (US)
- Cancer Treatment Centers of America (US)
- Norton Healthcare (US)
- Abington Memorial Hospital (US)
- University of California San Diego (US)
- NYU Langone Health (US)
- Memorial Healthcare System (US)
- Rongsheng Petrochemical (China) (CN)
- Eisai (United States) (US)
- Memorial Hospital (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108605
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00